Drug Search Results
More Filters [+]

Motesanib

Alternative Names: motesanib, amg 706
Latest Update: 2024-01-13
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: VEGFR1 Inhibitor,VEGFR2 Inhibitor,VEGFR3 Inhibitor,PGFR Inhibitor,KITl Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Motesanib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Pleural Effusion|Pericardial Effusion|Pleural Cancer

Phase 2: Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Thyroid Cancer|Breast Cancer|Carcinoid Tumor|Islet Cell Adenoma|Neuroendocrine Tumors|Fallopian Tube Cancer|Peritoneal Cancer|Malignant Carcinoid Syndrome|Ovarian Cancer

Phase 1: Oncology Solid Tumor Unspecified|Esophageal Cancer|Pancreatic Cancer|Lung Cancer|Colorectal Cancer|Lymphoma|Lymphoproliferative Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

10G.30

P2

Withdrawn

Breast Cancer

2015-09-01

CDR0000526256

P2

Completed

Gastrointestinal Cancer|Carcinoid Tumor|Neuroendocrine Tumors|Malignant Carcinoid Syndrome|Islet Cell Adenoma

2014-10-01

Asian Phase 3 Study

P3

Terminated

Non-Small-Cell Lung Cancer

2014-09-01

GOG-0170L

P2

Terminated

Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer

2013-07-01

Recent News Events